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Introduction
Leptin, the 16-kDa product of the obese (ob) gene [1] was
originally described as a regulator of food intake and energy
expenditure [2–4]. Leptin is constitutively produced by
adipocytes [1] but may also be expressed in stomach,
muscles, placenta and mammary epithelial cells [5]. Rodents
carrying mutation in the ob gene (ob/ob mice) [6] or in the
gene for the leptin receptor, ObR [7] (db/db mice [8], fa/fa
rats [9]), express an obese phenotype that, in the case of
ob/ob mice, may be reversed by leptin administration [3].
However, humans carrying a missense mutation in the leptin
gene display obesity as one symptom of a complex syn-
drome [10], and leptin replacement is efficient for this sub-
group of obese people [11]. Like leptin-deficient humans,
ob/ob and db/db mice show disturbed regulation of several
functions besides weight control, including hematopoiesis,
angiogenesis and the immune system. While ob/ob mice
show defective T-cell responses [12], thymic atrophy [13]
and a decreased level of circulating lymphocytes, they seem
to be hyper-responsive to monocyte/macrophage-activating
stimuli, and the level of circulating monocytes is increased
fourfold [14]. ob/ob mice and fa/fa rats show increased sen-
sitivity to lipopolysaccharide, tumor necrosis factor (TNF)
and IL-1, and reconstitution with leptin protects ob/ob mice
from TNF-induced lethality [15].
In mice, leptin production is increased by stimuli such as
TNF, IL-1 and lipopolysaccharide [16–18]. In rats, infec-
tion with Nippostrongylus brasiliensis results in increased
leptin production [19]. In humans, varying results concern-
ing leptin production in septic patients have been pre-
sented [20,21].
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Weight loss is typically found during severe infections, e.g. septic arthritis. The aim of our study was to
evaluate the role of leptin, regulator of food intake and energy expenditure, for the development of
Staphylococcus aureus-triggered arthritis. Leptin production was found to be decreased during murine
S. aureus-induced arthritis. Treatment with recombinant leptin neither restored the basal leptin levels
nor affected the weight loss during the disease, but it significantly decreased the severity of septic
arthritis. Exogenous leptin did not affect the staphylococcal load as measured in blood, joints and
kidneys. Preceding the effects on joint manifestations, serum levels of interleukin-6 decreased in leptin-
treated mice. In conclusion, the treatment with recombinant leptin reduced both the severity of joint
manifestations in S. aureus-induced arthritis and the inflammatory response, as measured by serum IL-
6 levels, without affecting the survival of bacteria in vivo.
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Septic arthritis is a highly and rapidly destructive hemato-
genously spread joint disease, which usually produces
sequelae in the affected person and can at worst cause
death [22]. The most common pathogen in bacterial arthri-
tis is Staphylococcus aureus [23], which in patients with
rheumatoid arthritis is the causative organism in approxi-
mately 75% of cases [24].
While leptin levels do not correlate with disease activity in
patients with rheumatoid arthritis [25], the impact of
S. aureus-induced infection, or septic arthritis, on leptin
production has not been investigated. We first measured
leptin levels in NMRI and C57BL/6 mice before and after
intravenous inoculation with S. aureus. Both mouse strains
showed a decrease in leptin levels during the course of
infection. The effect of leptin on the severity of S. aureus-
induced arthritis is unknown. We therefore administered
recombinant leptin to the mice during the course of infec-
tion. While the exogenously added leptin did not affect
survival of the mice or bacterial clearance, the severity of
septic arthritis was significantly lower in leptin-treated
mice than in control animals.
Materials and methods
Mice, bacteria and infection
Male 5- to 8-week-old C57BL/6 and NMRI mice (B&K
Universal, Uppsala, Sweden) were used throughout the
study. Mice were housed, fed and intravenously inoculated
as described elsewhere [26]. For administration of recom-
binant mouse leptin (rleptin) (R&D Systems, Abingdon,
Oxon, UK), the mice were given intraperitoneal injections
of 0.2 ml twice daily (50 µg/mouse per day [27]), the first
dose being given 2 hours before inoculation of bacteria.
Control animals received phosphate-buffered saline
(PBS). Intra-articular injections of rleptin were given in a
knee joint in a volume of 30 µl containing 40 µg/ml. PBS
was used as control injection.
Experimental protocol
Experiment 1 was performed using 13 male C57BL/6
mice. Nine mice were each intravenously inoculated with
1 . 6×1 0 7 S. aureus per mouse. Four control mice
received PBS. The mice were bled at regular intervals and
blood was collected on days 1, 8 and 11.
In experiment 2, 20 male NMRI mice received 8 × 106
S. aureus per mouse, given intravenously. Ten mice were
given intraperitoneal injections of rleptin and 10 of PBS on
day 0. They were bled on day –1, day 1 and day 8, and
were killed at day 8. The kidneys were removed to check
for the presence of bacteria, and the four paws were kept
for histopathological examination.
Experiment 3 differed from experiment 2 in that the mice
were bled only on day 1, to check for the presence of
staphylococci in the blood, and that the joints were
checked for the presence of staphylococci on day 8.
In experiment 4, the setup was the same as in experiments
2 and 3. The mice were killed on day 2 and the paws were
kept for histopathological examination.
In experiment 5, four male C57BL/6 mice were used. They
were given an intra-articular injection of leptin into one
knee and of PBS into the other knee, as described above.
The mice were killed 3 days after inoculation and the
knees were kept for histopathological examination.
Evaluation of arthritis and weight
All mice were labeled and monitored individually. Their
limbs were inspected by two observers at regular inter-
vals. Clinical examinations for arthritis and histopathologi-
cal examinations were performed as described elsewhere
[26]. To evaluate the intensity of synovitis and of cartilage
and bone destruction, we used a histological index based
on microscopic inspection, assigning a score of 0–3
points for each joint (elbow, wrist, carpal joints, fingers,
knee, ankle, tarsal joints and toes) with regard to synovial
hypertrophy and to destruction of cartilage and bone. Syn-
ovitis was scored as follows: 0 = no synovial hypertrophy;
1 = mild synovial hypertrophy, consisting of up to five cell
layers; 2 = moderate hypertrophy, up to 10 cell layers; 3 =
marked hypertrophy, >10 cell layers. Cartilage and bone
destruction were each scored separately, as follows: 0 =
no destruction; 1 = mild destruction; 2 = moderate
destruction; 3 = severe destruction; the scores for carti-
lage and for bone were summed to yield an overall score
for cartilage and bone. The total index was calculated by
adding all the scores within each animal tested.
Determination of bacterial load
Bacterial samples were obtained as described elsewhere
[26]. Colonies were tested for reactivity to catalase (using
18% hydrogen peroxide) and to coagulase (using rabbit
plasma with EDTA [Becton Dickinson Microbiology
Systems, Sparks, MD, USA]).
Cytokine reagents and analyses
rleptin (R&D Systems) was reconstituted in accordance
with the manufacturer’s instructions, then further diluted in
PBS to achieve the desired concentrations.
IFN-γ and IL-6 were measured as described elsewhere
[28]. Leptin, TNF, IL-1β and IL-10 were measured using
Quantikine mouse immunoassays (R&D Systems). Assays
were performed in accordance with the manufacturer’s
instructions.
Statistics
The Mann–Whitney U test, the Wilcoxon signed rank sum
test and Fisher’s exact test were used to analyse the data.P ≤ 0.05 was regarded as statistically significant. Serum
concentration of cytokines and bacterial content in tissues
are expressed as means ± SEM.
Results
Decreased leptin production during septic arthritis
The serum leptin concentration before inoculation of
staphylococci ranged from 1.0 to 8.0 ng/ml (median
2.5 ng/ml). Previous studies measuring leptin in C57BL/6
mice have found similar levels [16,29]. The serum concen-
tration of leptin decreased during S. aureus-induced
arthritis (Fig. 1a). This decrease was preceded by weight
loss (Fig. 1b). Controls showed weight increases of
21 ± 2.8% during the experiment, with a median leptin
level of 2.5 ng/ml at the end of the experiment. Leptin pro-
duction also decreased in infected NMRI mice treated
with rleptin (Fig. 1c).
Decreased severity of septic arthritis after treatment
with leptin
The severity of S. aureus-induced arthritis was signifi-
cantly decreased after the administration of rleptin (Fig. 2).
The treatment did not significantly affect the frequency of
arthritis at day 7 (67% in leptin-treated mice versus 84%
in controls).
The destruction of bone and cartilage was not significantly
affected by the addition of rleptin. At day 8, 89% in each
group showed such destruction, and the severity score
was 10 versus 16 (median, leptin-treated vs controls, n.s.).
In each group, 89% displayed synovitis; the median sever-
ity score was 8 versus 12 (treated vs controls, n.s.).
Decreased interleukin-6 production in leptin-treated
mice with septic arthritis
The leptin-treated mice had significantly lower IL-6 levels
than the controls at day 1, before the differences in joint
pathology appeared (1.1 ± 0.3 ng/ml vs 1.4 ± 0.1 ng/ml;
P = 0.049). At this early time-point, the serum concentra-
tion of IL-1β was 5.2 ± 0.8 pg/ml, vs 4.6 ± 1.6 pg/ml
(leptin-treated vs controls, n.s.), and for TNF it was
21 ± 13 pg/ml versus 15 ± 5 pg/ml (leptin-treated vs con-
trols, n.s.). Serum IL-10 was not detectable. Serum IFN-γ
in leptin-treated and control mice was 473 ± 97 and
446 ± 145 pg/ml, respectively (n.s.). At day 8, no signifi-
cant differences were found.
Administration of leptin does not influence mortality,
weight loss or staphylococcal load in tissues
Ten percent (2/20) of the leptin-treated mice died during
the two 8-day experiments, versus 5% (1/20) of controls.
No effect of exogenous leptin on weight loss was
recorded, either early or late. At the end of the experiment,
the mean weight loss was 18% in both groups. The load
of  S. aureus in kidneys was 2.1 ± 1.5 × 108  (leptin-
treated) versus 3.7 ± 1.6 × 108 (controls; n.s.). In blood
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Figure 1
Box-and-whisker plots of (a) serum concentration of leptin; (b) weight
change in C57BL/6 mice (n = 9), before and after inoculation with S.
aureus; and (c) serum concentration of leptin in leptin-treated NMRI
mice (n = 10) during S. aureus-induced arthritis (experiment 2). Boxes
show the medians and upper and lower quartiles. Whiskers show the
10th and 90th percentiles. The highest and lowest values are plotted
as circles. The Wilcoxon signed rank sum test was used to evaluate
statistical significance. n.s. = not significant.
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(c)24 hours after the inoculation of staphylococci, leptin-
treated animals had 390 ± 151 colony-forming units per
milliliter, vs 84 ± 36 for controls (n.s.). Six of nine leptin-
treated mice and 8 of 10 PBS-treated controls had S.
aureus present in joints (n.s.).
Discussion
This is the first report of a study of leptin production in
response to bacterial arthritis. The leptin production was
clearly downregulated during S. aureus-induced arthritis.
Furthermore, this study is the first to show that the severity
of arthritis is lower in leptin-treated mice than in controls.
Before any ameliorating effect of leptin on arthritis was
evident, a decreased inflammatory response was noted,
as measured by serum IL-6 levels.
Leptin has been shown to be involved in inflammation,
both as its initiator and as a downregulator. The adminis-
tration of rleptin induces production of proinflammatory
cytokines, e.g. TNF [30], and directs a T-cell response into
a Th1 type of response [27]. Leptin is proinflammatory in
case of initiation and progression of experimental autoim-
mune encephalomyelitis [31]. In this study, we evaluated if
leptin itself could initiate joint inflammation, but no signs of
synovitis were seen when knees were exposed to micro-
gram doses of the molecule (results not shown).
Besides being an inducer of proinflammatory mediators,
leptin may be induced by, for example, TNF and IL-1β.
Since anorexia is one of the symptoms of murine septic
arthritis, and the production of several proinflammatory
cytokines is increased during the course of disease, we
hypothesized that anorexia could be induced by increased
leptin production during S. aureus-induced arthritis. Unex-
pectedly, leptin production was significantly decreased
during S. aureus-induced arthritis. The decreased leptin
production in mice with septic arthritis may mirror a
decreased volume of leptin-producing adipose tissue.
Interestingly, while weight was almost restored after the
anorectic phase, leptin production stayed low, possibly
reflecting a decreased volume of fat tissue.
Previous reports on the correlation between leptin and
arthritis are rare [25]. Our data show that the administra-
tion of rleptin leads to a decreased severity of septic
arthritis, indicating an anti-inflammatory effect. Leptin has
previously been reported to exert a protective role
against endotoxin-induced lethality, possibly mediated
through increasing levels of IL-10 and IL-1-receptor
antagonist [32] or through downregulation of TNF pro-
duction [33]. Leptin also mediates the protection of TNF-
induced lethality [15]. The proinflammatory importance
of TNF/lymphotoxin-α and TNF itself for the development
of septic arthritis has been described elsewhere [34].
Potentially, exogenous leptin may exert its anti-inflamma-
tory effect on septic arthritis through protection against
TNF-mediated inflammation rather than downregulation
of TNF production. Indeed, our experiments did not show
any significant differences with respect to circulating
TNF levels in leptin-treated versus control mice. The
decreased production of IL-6 in response to exogenous
leptin might be a possible pathway. Decreased produc-
tion of IL-6 could be due to a downregulation of TNF, or,
alternatively, could be a direct effect of leptin. There are
some indications that leptin directly influences the pro-
duction of IL-6. Macrophages from ob/ob mice display
increased expression of IL-6 [35]. Similarly, overexpres-
sion of superoxide and hydrogen peroxide is seen in
macrophages from these leptin-deficient mice. These
findings indicate that in leptin shortage, whether this is of
genetic origin or due to induction of an anorectic condi-
tion, macrophages are overactivated because of lack of
leptin control. IL-6 itself is an important proinflammatory
cytokine in noninfectious arthritis [36], and decreased
production of this cytokine might be an important anti-
inflammatory pathway by which rleptin ameliorates septic
arthritis. Additional anti-inflammatory pathways induced
by leptin may include, for example, increased production
of IL-1Ra [37].
We did not find any differences with regard to clearance
of staphylococci from the blood stream, joints or kidneys,
though results in vitro indicate potential antibacterial
effects of leptin either through increased phagocytosis
[38,39] or through enhanced production of reactive
oxygen species [40].
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Figure 2
Box-and-whisker plots showing the severity of S. aureus-induced
arthritis in leptin-treated NMRI mice (n = 20) and PBS-injected
controls (n = 20), expressed as arthritic index (experiments 2 and 3).
Boxes show the medians and the upper and lower quartiles. Whiskers
show the 10th and 90th percentiles. The two highest and two lowest
values are plotted as circles. The Mann–Whitney U test was used to
evaluate statistical significance.
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P = 0.018Conclusion
The production of leptin is decreased during the course of
S. aureus-induced arthritis, probably because of a vast
loss of adipose tissue, which is the professional leptin pro-
ducer. The administration of rleptin decreases the severity
of septic arthritis without affecting weight loss or the bac-
terial load in tissues. The beneficial effects of leptin on the
development of arthritis are preceded by downregulation
of interleukin-6 production. While potent anti-inflammatory
interventions, e.g. neutralizing TNF, might result in accu-
mulation of staphylococci in various tissues during septic
arthritis and potentially decrease survival, leptin might offer
an anti-inflammatory regimen with less harmful undesired
effects.
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